评论“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”。
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
机构信息
University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Department of Haematology, Imperial College London, London W12 0HS, UK.
出版信息
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aau0416.
Abstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.
摘要
LB100 不会使 CML 干细胞对酪氨酸激酶抑制剂诱导的细胞凋亡敏感。
相似文献
1
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".评论“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aau0416.
2
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".对“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”一文的评论的回应。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aav0819.
3
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia.PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感。
Sci Transl Med. 2018 Feb 7;10(427). doi: 10.1126/scitranslmed.aan8735.
4
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.新型 HDAC 抑制剂 MAKV-8 与伊马替尼协同抑制 BCR-ABL/MYC 信号通路杀伤慢性髓系白血病细胞：对伊马替尼耐药和干细胞的影响。
Clin Epigenetics. 2020 May 19;12(1):69. doi: 10.1186/s13148-020-00839-z.
5
Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.靶向慢性粒细胞白血病中的BLT2可抑制白血病干/祖细胞功能。
Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.
6
7
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.PP2A 激活剂药物选择性根除 TKI 耐药性慢性髓性白血病干细胞。
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
8
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.miR-29a-3p、miR-494-3p和miR-660-5p的表达失调会影响慢性粒细胞白血病白血病干细胞对酪氨酸激酶抑制剂的敏感性。
Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.
9
BCR-ABL kinase is dead; long live the CML stem cell.BCR-ABL 激酶已死；慢性髓系白血病干细胞长存。
J Clin Invest. 2011 Jan;121(1):22-5. doi: 10.1172/JCI43605. Epub 2010 Dec 13.
10
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.组蛋白去乙酰化酶 6 抑制剂 7b 诱导 BCR-ABL 泛素化和下调，并与伊马替尼协同作用，引发慢性髓性白血病细胞凋亡。
Pharmacol Res. 2020 Oct;160:105058. doi: 10.1016/j.phrs.2020.105058. Epub 2020 Jun 30.
引用本文的文献
1
Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer's disease.三十年来的 SET/TAF1β/I2PP2A：从鉴定生物功能到其在癌症和阿尔茨海默病中的意义。
Biosci Rep. 2022 Nov 30;42(11). doi: 10.1042/BSR20221280.
2
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.慢性髓性白血病的耐药机制及其对治疗策略的影响
Cancers (Basel). 2022 Jul 6;14(14):3300. doi: 10.3390/cancers14143300.
3
Targeting Phosphatases and Kinases: How to Checkmate Cancer.靶向磷酸酶和激酶：如何“将死”癌症。
Front Cell Dev Biol. 2021 Oct 28;9:690306. doi: 10.3389/fcell.2021.690306. eCollection 2021.
4
Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.慢性髓性白血病中酪氨酸激酶与磷酸酶相互作用的当前观点
Cancers (Basel). 2021 May 12;13(10):2311. doi: 10.3390/cancers13102311.
5
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions.耐药性白血病干细胞的持续存在和 CML 患者 NK 细胞免疫受损依赖于抗增殖和 PP2A 激活功能。
Blood Cancer Discov. 2020 Jul;1(1):48-67. doi: 10.1158/0008-5472.BCD-19-0039.
本文引用的文献
1
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.B 细胞特异性葡萄糖碳利用途径的改变揭示了 B 细胞恶性肿瘤的独特弱点。
Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.
2
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia.PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感。
Sci Transl Med. 2018 Feb 7;10(427). doi: 10.1126/scitranslmed.aan8735.
3
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.蛋白磷酸酶 2A 抑制剂 LB-100 治疗复发性实体瘤患者的安全性、耐受性和初步疗效：一项开放标签、剂量递增、首次人体、I 期临床试验。
Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.
4
From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.从 PP2A 的生物学到治疗血液系统恶性肿瘤的 PADs。
Front Oncol. 2015 Feb 16;5:21. doi: 10.3389/fonc.2015.00021. eCollection 2015.
5
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.PP2A 激活剂药物选择性根除 TKI 耐药性慢性髓性白血病干细胞。
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
6
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.AHI-1与BCR-ABL相互作用，并调节BCR-ABL的转化活性以及慢性粒细胞白血病干/祖细胞对伊马替尼的反应。
J Exp Med. 2008 Oct 27;205(11):2657-71. doi: 10.1084/jem.20072316. Epub 2008 Oct 20.
Zotero 插件